Holen Sie sich die Stockscreener-App
1.98
8.79%
0.16
Handel nachbörslich:
2.00
0.02
+1.01%
Schlusskurs vom Vortag:
$1.82
Offen:
$1.82
24-Stunden-Volumen:
78,952
Relative Volume:
2.61
Marktkapitalisierung:
$1.16M
Einnahmen:
$598.00K
Nettoeinkommen (Verlust:
$-44.93M
KGV:
-0.2383
EPS:
-8.31
Netto-Cashflow:
$-17.32M
1W Leistung:
+5.32%
1M Leistung:
-39.73%
6M Leistung:
-64.23%
1J Leistung:
-92.58%
1-Tages-Spanne:
$1.81
$2.13
1-Wochen-Bereich:
$1.76
$2.13
52-Wochen-Spanne:
$1.75
$39.38
Ernexa Therapeutics Inc Stock (ERNA) Company Profile
Firmenname
Ernexa Therapeutics Inc
Sektor
Branche
Telefon
(617) 798-6700
Adresse
1035 CAMBRIDGE STREET, CAMBRIDGE
Vergleichen Sie ERNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ERNA
Ernexa Therapeutics Inc
|
1.98 | 1.16M | 598.00K | -44.93M | -17.32M | -8.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Ernexa Therapeutics Inc Aktie (ERNA) Neueste Nachrichten
Ernexa Therapeutics (NASDAQ:ERNA) Shares Up 5.9% – What’s Next? - Defense World
Sector Update: Health Care - MarketScreener
Ernexa Therapeutics Shares Fall Pre-Bell Following Reverse Stock Split - marketscreener.com
Ernexa Therapeutics stock plummets on announcing 1-for-15 reverse stock split - MSN
Ernexa Therapeutics announces 1-for-15 reverse stock split By Investing.com - Investing.com South Africa
Eterna Therapeutics Implements 1-for-15 Reverse Stock Split - TipRanks
Ernexa Therapeutics announces 1-for-15 reverse stock split - Investing.com
Ernexa Therapeutics registers 57M shares for resale - MSN
Ernexa therapeutics ten percent owner acquires $2.22 million in stock By Investing.com - Investing.com Nigeria
Ernexa therapeutics ten percent owner acquires $2.22 million in stock - Investing.com Australia
Eterna Therapeutics Files for Resale of 57 Million Shares - marketscreener.com
Ernexa Announces 1-for-15 Reverse Stock Split Effective June 12 To Regain Nasdaq Compliance - Nasdaq
Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split - citybiz
Ernexa Stock Drops On 1-For-15 Reverse Stock Split To Regain Nasdaq Compliance: Retail Sentiment Improves But Stays Bearish - MSN
Ernexa Therapeutics Announces 1-For-15 Reverse Stock Split - marketscreener.com
Ernexa Plans 93% Share Reduction in Critical Nasdaq Compliance Move - Stock Titan
Eterna Therapeutics Completes $6M Private Placement - TipRanks
Eterna Therapeutics Increases Authorized Shares and Amends Bylaws - TipRanks
Ernexa Therapeutics announces new data to be presented at ASCO meeting 2025 - TipRanks
Ernexa Therapeutics to Present Breakthrough Data on iMSC-Based Immunotherapy at ASCO Annual Meeting 2025 - Nasdaq
Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025 - GlobeNewswire
Ernexa Therapeutics Establishes Texas Subsidiary to Support - GlobeNewswire
Ernexa's New Texas Hub Accelerates Novel Ovarian Cancer Treatment: MD Anderson Expert Leads Research - Stock Titan
Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference - The Kingston Whig Standard
ERNAErnexa Latest Stock News & Market Updates - Stock Titan
Can Ernexa Crack Ovarian Cancer with Novel Stem Cell Approach? - Inside Precision Medicine
Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025 - GlobeNewswire
Revolutionary Stem Cell Therapy Fights Cancer in Two Ways, MD Anderson Study Shows - Stock Titan
Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025 - The Manila Times
Revolutionary Tumor-Fighting Cell Therapy: MD Anderson to Present Ernexa's Ovarian Cancer Breakthrough at AACR - Stock Titan
Ernexa Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:ERNA - Benzinga
Ernexa Therapeutics Inc Files Prospectus For Resale Of 10.4 Million Shares Of Common Stock By Selling Stockholder- SEC Filing - marketscreener.com
Smart Trial Design In Cell Therapy: Fast-Tracking Without Compromising - Clinical Leader
Eterna therapeutics sees $394,174 stock acquisition by Charles Cherington - Investing.com Australia
ERNA stock touches 52-week low at $0.16 amid sharp annual decline - Investing.com India
Ernexa Therapeutics Closes New Funding Round - GlobeNewswire
Biotech Breakthrough: Ernexa Secures $7.25M to Advance Revolutionary Cancer Treatment - Stock Titan
Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
Eterna Therapeutics announces corporate rebranding to Ernexa Therapeutics By Investing.com - Investing.com Australia
Eterna Therapeutics announces corporate rebranding to Ernexa Therapeutics - Investing.com
Eterna Therapeutics Changes Name to Ernexa Therapeutics to - GlobeNewswire
Major Pivot: Eterna Becomes Ernexa, Unveils New Cancer and Autoimmune Disease Strategy - Stock Titan
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World
Finanzdaten der Ernexa Therapeutics Inc-Aktie (ERNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ernexa Therapeutics Inc-Aktie (ERNA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cherington Charles | 10% Owner |
Apr 02 '25 |
Buy |
0.10 |
3,768,397 |
394,174 |
20,401,602 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):